MacroGenics, Inc. (MGNX) AI Stock Analysis

MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, focused on developing and commercializing antibody-based therapeutics for cancer treatment in the United States. Its flagship product is MARGENZA (margetuximab-cmkb), a HER2 antagonist approved with chemotherapy for metastatic HER2-positive breast cancer in adult patients who received two or more prior anti-HER2 regimens. The company's pipeline includes MGC018 and Enoblituzumab targeting B7-H3 in solid tumors, MGD024 targeting CD123 and CD3 for hematologic cancers, Lorigerlimab targeting PD-1 and CTLA-4, Tebotelimab targeting PD-1 and LAG-3, and Retifanlimab for metastatic squamous cell carcinoma of the anal canal and non-small cell lung cancer.

Annual revenue fluctuated from $75.6M in FY2021 to $151.9M in FY2022, dropping to $57.2M in FY2023 before recovering to $148.3M in FY2024 and $149.5M in FY2025, delivering a 5-year revenue CAGR of 8.9%. Gross margin decreased from 96.5% in FY2021 to 71.1% in FY2025. The company has reported ongoing net losses, including a net income of -$74.6M and an EPS of -$1.17 in FY2025. For the trailing twelve months, revenue reached $175.1M with an operating margin of -42.2%. In the latest quarter ended June 30, 2026, quarterly revenue grew 378.0% year-over-year, while quarterly earnings declined 70.4%.

As of June 30, 2026, MacroGenics maintained $173.3M in cash and short-term investments alongside $35.1M in total debt, yielding net cash of $138.2M. Total assets stood at $345.4M against shareholders' equity of $42.9M, with a current ratio of 2.96 and a debt-to-equity ratio of 0.82. In FY2025, operating cash flow was -$81.0M and free cash flow was -$83.0M, with capital expenditures totaling $1.9M. Over five years, the share count grew 4.0%.

At a market cap of $207.0M and enterprise value of $104.5M, MacroGenics trades at a price-to-sales multiple of 1.2x and an EV-to-revenue multiple of 0.6x, compared to a price-to-sales median of 4.1x for its US-listed Healthcare peers. Its forward P/E ratio is 61.0x, above the median of 17.3x for US-listed Healthcare peers, with a PEG ratio of 0.01. Over the past year, the stock returned 92.3%, outperforming the S&P 500 return of 16.8%, but its 5-year return of -83.5% trails the S&P 500 gain of 83.0%.

MacroGenics is tracked by 7 analysts, with 2 Strong Buy, 1 Buy, and 4 Hold recommendations. The mean price target is $8.00, representing a 146.2% premium over the last close of $3.25. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $108.2M and an EPS of -$1.56. For the following fiscal year, analysts forecast revenue of $90.6M and an EPS of -$1.47. The company beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 11, 2026.

This page is an AI-written research summary of MacroGenics, Inc. (MGNX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MGNX income statement, MGNX balance sheet, MGNX key metrics, MGNX analyst forecast, MGNX chart. See the MGNX stock overview for the latest quote and news.